Efalizumab for Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Raptiva will have beneficial effects in the
treatment of patients with moderate to severe atopic dermatitis.